cGMP production and analysis of BG505 SOSIP. 664, an extensively glycosylated, trimeric HIV‐1 envelope glycoprotein vaccine candidate
AK Dey, A Cupo, G Ozorowski… - Biotechnology and …, 2018 - Wiley Online Library
We describe the properties of BG505 SOSIP. 664 HIV‐1 envelope glycoprotein trimers
produced under current Good Manufacturing Practice (cGMP) conditions. These proteins are …
produced under current Good Manufacturing Practice (cGMP) conditions. These proteins are …
[HTML][HTML] Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25
Abstract The Plasmodium falciparum Pfs25 protein (Pfs25) is a leading malaria transmission-
blocking vaccine antigen. Pfs25 vaccination is intended to elicit antibodies that inhibit …
blocking vaccine antigen. Pfs25 vaccination is intended to elicit antibodies that inhibit …
Characterization of the human immunodeficiency virus (HIV-1) envelope glycoprotein conformational states on infectious virus particles
ABSTRACT Human immunodeficiency virus (HIV-1) entry into cells involves triggering of the
viral envelope glycoprotein (Env) trimer ([gp120/gp41] 3) by the primary receptor, CD4, and …
viral envelope glycoprotein (Env) trimer ([gp120/gp41] 3) by the primary receptor, CD4, and …
[HTML][HTML] Env exceptionalism: why are HIV-1 Env glycoproteins atypical immunogens?
PJ Klasse, G Ozorowski, RW Sanders, JP Moore - Cell host & microbe, 2020 - cell.com
Recombinant HIV-1 envelope (Env) glycoproteins of ever-increasing sophistication have
been evaluated as vaccine candidates for over 30 years. Structurally defined mimics of …
been evaluated as vaccine candidates for over 30 years. Structurally defined mimics of …
[HTML][HTML] Networks of HIV-1 envelope glycans maintain antibody epitopes in the face of glycan additions and deletions
GE Seabright, CA Cottrell, MJ van Gils, A D'addabbo… - Structure, 2020 - cell.com
Numerous broadly neutralizing antibodies (bnAbs) have been identified that target the
glycans of the HIV-1 envelope spike. Neutralization breadth is notable given that glycan …
glycans of the HIV-1 envelope spike. Neutralization breadth is notable given that glycan …
[HTML][HTML] Key gp120 glycans pose roadblocks to the rapid development of VRC01-class antibodies in an HIV-1-infected Chinese donor
VRC01-class antibodies neutralize diverse HIV-1 strains by targeting the conserved CD4-
binding site. Despite extensive investigations, crucial events in the early stage of VRC01 …
binding site. Despite extensive investigations, crucial events in the early stage of VRC01 …
[HTML][HTML] Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics
A Torrents de la Peña, K Rantalainen… - PLoS …, 2019 - journals.plos.org
The HIV-1 envelope glycoprotein (Env) trimer is located on the surface of the virus and is the
target of broadly neutralizing antibodies (bNAbs). Recombinant native-like soluble Env …
target of broadly neutralizing antibodies (bNAbs). Recombinant native-like soluble Env …
Alterations in gp120 glycans or the gp41 fusion peptide-proximal region modulate the stability of the human immunodeficiency virus (HIV-1) envelope glycoprotein …
The human immunodeficiency virus (HIV-1) envelope glycoprotein (Env) trimer mediates
entry into host cells by binding receptors, CD4 and CCR5/CXCR4, and fusing the viral and …
entry into host cells by binding receptors, CD4 and CCR5/CXCR4, and fusing the viral and …
[PDF][PDF] The core domain of hepatitis C virus glycoprotein E2 generates potent cross‐neutralizing antibodies in guinea pigs
PT Vietheer, I Boo, J Gu, K McCaffrey, S Edwards… - …, 2017 - Wiley Online Library
A vaccine that prevents hepatitis C virus (HCV) infection is urgently needed to support an
emerging global elimination program. However, vaccine development has been confounded …
emerging global elimination program. However, vaccine development has been confounded …
[HTML][HTML] Structural vaccinology for viral vaccine design
Although vaccines have proven pivotal against arrays of infectious viral diseases, there are
still no effective vaccines against many viruses. New structural insights into the viral …
still no effective vaccines against many viruses. New structural insights into the viral …